Efavirenz dose reduction in HIV-infected patients

HIV Medicine

Volumn 13, Issue 4, 2012, Pages 252-253

  Lanzafame, M ^a   Bonora, S ^b   Lattuada, E ^a   Vento, S ^c  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF BOTSWANA   (Botswana)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; VIRUS RNA;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; PRIORITY JOURNAL; SLEEP DISORDER; TREATMENT DURATION;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; FEMALE; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84857932047     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00964.x     Document Type: Letter

References (5)

1. th World AIDS Conference. Geneva, Switzerland, June 1998 [Abstract 22334].
2. ENCORE Trial. Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals. Available at (accessed 21 May 2011).
3. D'Avolio A, Baietto L, Siccardi M etal. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30: 662-669.
4. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 71-75.
5. Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007; 8: 19-23.